Search

Displaying results 6391 - 6400 of 9705 in total
  1. Drug

    Benzyl benzoate

    go.drugbank.com/drugs/DB00676
    Approved

    Scabies is a skin infection caused by the mite sarcoptes scabiei. It is characterised by severe itching (particularly at night), red spots, and may lead to a secondary infection.

    Categories: Compounds used in a research, industrial, or household settingProducts: DRISUL-L® 30 % LOCIÓN TÓPICA
  2. Drug

    Cryptenamine

    go.drugbank.com/drugs/DB00785
    Approved

    Cryptenamine is a mixture of closely related hypotensive alkaloids from Veratrum album (Liliaceae). … Cryptenamine has a marked and re-producible depressor effect when given intravenously to hypertensive patients, however the mechanism of action is not known.

  3. Drug

    Trabedersen

    go.drugbank.com/drugs/DB05697
    Investigational

    Synonyms: DNA, D(P-THIO)(C-G-G-C-A-T-G-T-C-T-A-T-T-T-T-G-T-A)
  4. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    ALS-08 is a proprietary creatine-derivative that is being developed as a potential therapeutic for amyotrophic lateral sclerosis (ALS). It is being developed by Avicena Group, Inc.

  5. Drug

    EVT 201

    go.drugbank.com/drugs/DB05721
    Investigational

    EVT 201 is a novel partial positive allosteric modulator of the GABAA receptor complex which is being developed as a treatment for insomnia. It is being developed by Evotec Inc.

  6. Drug

    alpha-Conotoxin VC 1.1

    go.drugbank.com/drugs/DB05724
    Experimental

  7. Drug

    PMI-001

    go.drugbank.com/drugs/DB05730
    Experimental

    PMI-001 is a stand-alone, disease-modifying, anti-rheumatic drug (DMARD) being developed by Phytomedics Inc.

  8. Drug

    Cefilavancin

    go.drugbank.com/drugs/DB05735
    Investigational

    Cefilavancin is a covalently-linked glycopeptide-cephalosporin (beta-lactam) heterodimer antibiotic that exhibits substantially greater activity than its component parts against Gram-positive bacteria.

  9. Drug

    AGS-005

    go.drugbank.com/drugs/DB05741
    Experimental

    AGS-005 is a personalized dendritic cell-based immunotherapy, with optimized immune response characteristics, that is designed to stimulate the patient's immune system to target and destroy the patient's

  10. Drug

    AGS-004

    go.drugbank.com/drugs/DB05742
    Investigational

    A personalized immunotherapy addresses these issues because it is able to capture private viral mutations, providing a matched, complete immune response for each individual HIV patient. … This approach may overcome the weaknesses of other available therapies and therefore could result in a better chance of success for HIV treatment.